Schütz-Fuhrmann Ingrid, Stadler Marietta, Zlamal-Fortunat Sandra, Rami-Merhar Birgit, Fröhlich-Reiterer Elke, Hofer Sabine E, Mader Julia, Resl Michael, Bischof Martin, Kautzky-Willer Alexandra, Weitgasser Raimund
3. Medizinische Abteilung mit Stoffwechselerkrankungen und Nephrologie, Krankenhaus Hietzing, Wolkersbergenstraße 1, 1130, Wien, Österreich.
Diabetes Research Group, King's College London, London, Großbritannien.
Wien Klin Wochenschr. 2019 May;131(Suppl 1):47-53. doi: 10.1007/s00508-019-1485-6.
This position statement is based on current evidence available on the safety and benefits of continuous subcutaneous insulin infusion therapy (CSII, pump therapy) in diabetes with an emphasis on the effects of CSII on glycemic control, hypoglycaemia rates, occurrence of ketoacidosis, quality of life and the use of insulin pump therapy in pregnancy. The current article represents the recommendations of the Austrian Diabetes Association for the clinical praxis of insulin pump treatment in children, adolescents and adults.
本立场声明基于目前有关糖尿病持续皮下胰岛素输注治疗(CSII,胰岛素泵治疗)的安全性和益处的现有证据,重点关注CSII对血糖控制、低血糖发生率、酮症酸中毒的发生、生活质量以及孕期胰岛素泵治疗使用情况的影响。本文代表了奥地利糖尿病协会对儿童、青少年和成人胰岛素泵治疗临床实践的建议。